Non-hodgkin Lymphoma,B Cell Clinical Trial
TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma
|Source||Timmune Biotech Inc.|
|Phone||+86 0731 83928147|
|Phase||Phase 1/Phase 2|
|Start date||May 10, 2018|
|Completion date||December 31, 2020|
This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).
The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the TriCAR-T-CD19 to simultaneously targeting the CD19 positive NHL，blocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion.
|Not yet recruiting||
||Phase 1/Phase 2|